Purpose: The effect of allergic rhinitis (AR) on autonomic nervous system in patients with obstructive sleep apnea (OSA) remains unclear. We utilized heart rate variability (HRV) analysis to assess cardiac autonomic activity in patients with OSA, comparing those with and without allergic rhinitis (AR).
Methods: We enrolled 182 patients who visited our sleep clinic complaining of habitual snoring or apnea during sleep.
Hepatitis B virus (HBV) can cause chronic infections, significantly increasing the risk of death from cirrhosis and hepatocellular carcinoma (HCC). A key player in chronic HBV infection is covalently closed circular DNA (cccDNA), a stable episomal form of viral DNA that acts as a persistent reservoir in infected hepatocytes and drives continuous viral replication. Despite the development of several animal models, few adequately replicate cccDNA formation and maintenance, limiting our understanding of its dynamics and the evaluation of potential therapeutic interventions targeting cccDNA.
View Article and Find Full Text PDFOur prior findings showed that BCL2A1 in neutrophils is highly expressed in the extra-placental membranes (EPMs) of both the human spontaneous preterm-birth (PTB) (i.e., PTL or preterm PROM) and nonhuman-primate PTB model.
View Article and Find Full Text PDFObjectives: Long work hours and weekend work can negatively impact worker sleep; however, gender differences in these relationships have not been sufficiently studied. We explored the association between long work hours, weekend work, and insomnia symptoms, as well as the moderating effect of gender on this association.
Methods: A nationwide sample of 42,476 Korean workers (52.
Background: The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.
Methods: This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease.